Silicone breast implants (SBI) induce formation of a periprosthetic, often inflammatory, fibrovascular neo-tissue called a capsule. Histopathology of explanted capsules varies from densely fibrotic, acellular specimens to those showing intense inflammation with activated macrophages, multinucleated giant cells, and lymphocytic infiltrates. It has been proposed that capsuleinfiltrating lymphocytes comprise a secondary, bystander component of an otherwise benign foreign body response in women with SBIs. In symptomatic women with SBIs, however, the relationship of capsular inflammation to inflammation in other remote tissues remains unclear. In the present study, we utilized a combination of TCR -chain CDR3 spectratyping and DNA sequence analysis to assess the clonal heterogeneity of T cells infiltrating SBI capsules and remote, inflammatory tissues. TCR CDR3 fragment analysis of 22 distinct beta variable (BV) gene families revealed heterogeneous patterns of T cell infiltration in patients' capsules. In some cases, however, TCR BV transcripts exhibiting restricted clonality with shared CDR3 lengths were detected in left and right SBI capsules and other inflammatory tissues. DNA sequence analysis of shared, size-restricted CDR3 fragments confirmed that certain TCR BV transcripts isolated from left and right SBI capsules and multiple, extracapsular tissues had identical amino acid sequences within the CDR3 antigen binding domain. These data suggest that shared, antigen-driven T cell responses may contribute to chronic inflammation in SBI capsules as well as systemic sites of tissue injury.
Introduction
It is estimated that since the early 1960s approximately 1-2 million women have received silicone breast implants (SBIs) in the United States for reconstructive mammoplasty and cosmetic augmentation [1] . Despite this long history of clinical use, little is known about the nature and determinants of human immune responses induced by SBIs. In 1992, the U.S. Food and Drug Administration requested a voluntary moratorium on the use of SBIs following increased reports of SBI failures (e.g. leakage and rupture) and multiple cases of atypical connective tissue disease developing in some women with SBIs [2] [3] [4] . Since that time, considerable debate has ensued regarding the safety of SBIs particularly in regard to the immunopathologic consequences of silicone gel exposure. Although several epidemiological studies failed to detect an increased risk for the development of common connective tissue diseases after SBIs, these investigations were limited in their ability to assess risks for the development of rare or atypical autoimmune syndromes due to the size of the studies and various design and methodological limitations [4] [5] [6] .
SBIs, when implanted in the body, induce formation of a periprosthetic neo-tissue called a capsule. The development of this fibrovascular tissue is a dynamic process and often results in the formation of an organized and multilayered structure [5, 7] . At the surface of the SBI, a capsule consists of a layer of vacuolated phagocytic cells, known as a pseudosynovium, overlayed by a vascular connective tissue often containing inflammatory cells [1, 5, [8] [9] [10] [11] . These inflammatory cells include activated macrophages, multinucleated giant cells, and T and B lymphocytes [5, [11] [12] [13] . In some capsules, lymphocytes are seen surrounding tissue vacuoles and macrophages containing a highly refractile, non-polarizable foreign material morphologically and chemically consistent with silicone [9, 14, 15] .
Several lines of indirect evidence suggest that SBIs induce immune responses when implanted in humans and animals. These data include the presence of chronic lymphocytic infiltrates in SBI capsules [5, [11] [12] [13] , the adjuvant activity of some silicones in animals [16] , the development of humoral and cellular immune abnormalities following SBIs [5, [17] [18] [19] [20] [21] [22] [23] [24] [25] , T cell stimulatory responses induced by silicones in vitro [5, 21, 22] , and case reports describing connective tissue diseases in SBI recipients, some of which resolve following explantation [3, 6, [26] [27] [28] [29] . Based upon studies in humans and animals, it is clear that silicone gel diffuses from SBIs at the site of implantation and may migrate to multiple, distant organs and tissues [1, 5-7, 10, 30, 31] . What is uncertain, however, is whether any immunological relationship exists between local inflammatory responses detected in SBI capsules and systemic sites of tissue injury.
T lymphocytes are thought to contribute to pathology in many chronic inflammatory diseases [32, 33] . In SBI capsules, T cells comprise the majority of lymphocytes detected among inflammatory cells [11] [12] [13] . Whether capsule-infiltrating T cells accumulate in response to local antigenic stimulation or represent a secondary, bystander component of inflammation is unknown. Multiple studies of T cellmediated autoimmune disease in humans and animals have focused on the nature of TCR gene expression at sites of inflammation [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] . T cells express a diverse class of clonotypic TCRs. Among cells, cell-surface TCRs are encoded by functionally rearranged V, D ( -chain only), J, and C gene segments. The recognition of antigens by -TCRs is mediated, in part, by complementarity determining regions (CDR3) spanning the V(D)J junctions of rearranged TCR genes [42] . CDR3 sequence diversity is enhanced further by the addition and deletion of random nucleotides (designated N-regions) positioned between V, D, and J gene segments. Specific antigens are often recognized by T cells expressing a limited or restricted number of TCR V(D)J sequence combinations [32-35, 43, 44] . Such biases reflect strong selective pressures for specific amino acid sequences within the CDR3 antigen binding domain [42] . Consistent with these observations, studies of experimentally-induced and spontaneous forms of autoimmune disease have identified restricted and shared patterns of TCR gene expression among pathogenic T cells [32-37, 39-42, 44] .
Molecular studies of TCR gene expression have proven useful in identifying antigen-specific T cells in complex inflammatory infiltrates [32, 33, 36] . In a previous study, we examined patterns of TCR gene expression in 20 capsules from SBI recipients using a low resolution V gene family-specific RT-PCR assay [13] . These data indicated that similar patterns of TCR V gene expression were conserved between left and right SBI capsules in some implant recipients irrespective of clinical status. In the present study, we extend these findings utilizing a combination of high resolution TCR CDR3 spectratyping and direct DNA sequence analysis to assess the clonal heterogeneity of T cells found infiltrating SBI capsules and remote sites of tissue inflammation.
Materials and Methods

Patients and clinical material
The collection and analysis of clinical materials were done after obtaining informed patient consent for enrollment in IRB-approved clinical protocols. Clinical specimens, including blood samples and concurrent tissue biopsies were collected at the time of the surgical procedures. Portions of tissues were rapidly frozen on dry ice and stored at −80°C until processing. Three patients were studied extensively in this investigation. Patient #1 is a 46-year-old woman with a 20-year history of SBIs for augmentation (HLA DRB1*0403, 1501; DQA1*0102, 0301). She was diagnosed with rheumatoid factor-negative rheumatoid arthritis prior to SBI implantation, but later developed a syndrome consisting of severe systemic vasculitis, peripheral neuropathy, and worsening of her arthritis post-implantation. A bilateral explant was performed in response to her clinical status and a unilateral implant rupture. Patient #2 is a 41-year-old woman with a 13-year history of SBIs for augmentation (HLA DRB1* 0101, 1301; DQA1*0101, 0103). Post-implantation, she was diagnosed with an atypical connective tissue disease consisting of diffuse arthralgias, myalgias, chronic fatigue, and axillary lymphadenopathy. Explantation was performed in response to concerns about her worsening clinical status. Patient #3 is a 54-year-old woman with a 14-year history of SBIs placed during reconstructive mammoplasty after mastectomy for breast cancer (HLA DRB1*0403, 1501; DQA1*0102, 0301). She developed an undifferentiated connective tissue disease consisting of arthralgias, myalgias, chronic fatigue, diffuse rashes, systemic vasculitis, and a monoclonal gammopathy of undetermined significance postimplantation. Unilateral device rupture was noted upon explantation.
Immunohistology
Portions of tissues obtained at surgery were formalinfixed and paraffin-embedded for immunocytochemical analysis. Serial sections (five m) from each specimen were deparaffinized and subjected to microwave treatment [45, 46] . Processed sections were incubated with primary antibodies (CD3 and CD4, Novacastra, Newcastle, UK; CD8 and CD45RO, Dako, Carpinteria, CA, USA) and subsequently localized using a modified avidin-biotin immunoperoxidase method (Vector Laboratories, Burlingame, CA, USA).
RNA extraction, cDNA synthesis, and PCR amplification
Total RNA was isolated from tissues (200 mg/capsule or 50 mg/lymph node, muscle, or skin biopsy) and PBLs by homogenization followed by Trizol extraction (Gibco BRL, Gaithersburg, MD, USA). Purified RNA (5.0 g) was utilized for random-primed cDNA synthesis using the GeneAmp RT-PCR protocol (Perkin Elmer, Norwalk, CT, USA). The cDNA product was used for individual PCR amplifications (100 ng RNA equivalents per 25 l reaction) with one of 23 distinct 5′ TCR beta-variable (BV) gene-family-specific primers and a shared 6FAM-labeled 3′TCR BC gene primer according to established methods and nomenclature [47] [48] [49] . TCR BV10 and BV19 pseudogene families were excluded from the analysis [50] . PCR was performed for 35 (PBL) or 40 (tissues) cycles using a two-step cycling program (denaturation, 95°C for 15 s; annealing, 55°C for 20 s). Control amplifications for -actin (5′primer, caccttctacaatgagctgcg; 3′primer, tgcttgctgatccacatctgc) were performed from each sample to confirm cDNA integrity and assure that approximately equivalent amounts of cDNAs were utilized for TCR analysis (data not shown). Sensitivity of the TCR BV spectratyping assay was determined by spiking variable numbers of human Jurkat T cells (10 2 - 10 6 ) into serial sections of a noninflammatory SBI capsule prior to homogenization and RNA extraction. Based upon the assay conditions described above, the limit of TCR BV transcript detection was estimated between 10 2 -10 3 T cells (data not shown).
TCR spectratyping, DNA cloning, and sequence analysis
TCR BV gene family-specific amplification products were size-fractionated in 4.75% denaturing polyacrylamide gels and scanned directly with a fluorimager model SI (Molecular Dynamics, Sunnyvale, CA, USA) [48] . Patients' PBL and tissue samples were analysed in parallel to ensure assay integrity and confirm that tissue-derived PCR products corresponded with the predicted sizes of TCR BV gene amplification products detected in peripheral blood. For cloning analysis, TCR BV amplification products of interest were size-fractionated as described above, excised from polyacrylamide gels, crushed in 500 l of 50 mM TRIS (pH 8.0), and incubated overnight at +4°C. Eluted DNA (5 l) was subsequently re-amplified using corresponding 5′TCR BV primers and a nested 3′ TCR BC primer (5′gcgacctcgggtgggaacac3′) for 20 cycles as described above. The resulting amplification products were size-fractionated in 2% agarose gels and purified using the Qiaex gel extraction protocol (Qiagen Inc., Chatsworth, CA, USA). Eluted DNA was ligated within the pCR 2.1 T/A cloning vector (Invitrogen, Inc., San Diego, CA, USA) and used to transform bacterial cells as described by the manufacturer. Independent recombinants, identified by antibiotic selection and -galactosidase colorimetric assay, were grown overnight in mini-culture and screened subsequently by DNA dot blot hybridization using a TCR BC horseradish peroxidase-conjugated oligonucleotide probe and chemiluminescent detection as described previously [51] . Plasmid DNA, purified from positively-hybridizing bacterial lysates, was used as template for fluorescent dye terminator DNA sequencing with an ABI Model 377 automated sequencer (PE Applied Biosystems, Foster City, CA, USA). Nucleic acid and protein sequence comparisons were performed using PCGENE sequence analysis software (Intelligenetics, Mountain View, CA, USA).
Results
Immunohistopathology
We have evaluated 46 capsules to date and determined that their histopathology varied from nearly acellular, densely fibrotic capsules to those showing intense inflammation ( [11, 13] and unpublished results). Capsular infiltrates were generally comprised of activated macrophages, multinucleated giant cells, and variable numbers of T and B lymphocytes. In some instances, lymphocytes were seen surrounding tissue vacuoles and macrophages containing a highly refractile, foreign material consistent with that observed for silicone [14] . In a representative analysis, serial sections obtained from an inflammatory SBI capsule illustrate the orientation of CD4+and CD8+T cells co-expressing CD45RO, an anamnestic marker of T cell activation, around tissue vacuoles containing a material morphologically consistent with silicone ( Figure 1 ). The frequent detection of activated T cells found infiltrating SBI capsules prompted our examination of TCR gene expression for evidence of antigen-driven T cell responses.
TCR BV spectratype analysis
TCR spectratyping is a rapid and sensitive means of evaluating the clonal composition of T cells expressing a common V gene family based upon variations in the lengths of CDR3 antigen binding domains [48] . To examine the heterogeneity of T cells clones found infiltrating patients' tissues, we analysed CDR3 spectratypes for each of 22 distinct TCR BV gene families. We first validated the TCR BV CDR3 spectratyping assay by analysing a polyclonal population of T cells isolated from PBL of a healthy donor (Figure 2 ). The resulting fluorograph permits the discrimination of multiple, functionally rearranged TCR BV genefamily-specific transcripts. Variations in the lengths of intervening CDR3 regions produce the characteristic 'ladder' of bands (CDR3 spectratype) detected for each of the BV gene families. Adjacent bands in a given ladder vary by increments of three nucleotides (corresponding to one amino acid) within the CDR3 antigen binding domain. This representative analysis illustrates the heterogeneity of TCR BV gene expression consistent with the polyclonal composition of T cells in the peripheral blood.
Similar analyses of RNA isolated from 34 SBI capsules using a combination of low and high resolution TCR typing assays revealed that capsular T cell infiltrates varied widely and ranged from an absence of detectable TCR gene expression to the detection of multiple TCR V gene families ( [13] and data not shown). While the number and identity of TCR V gene families detected varied considerably among capsules, in some instances, shared and restricted patterns of V gene expression were detected in both the left and right capsules from individuals independent of their clinical status (i.e., symptomatic and asymptomatic patients). A representative TCR BV CDR3 spectratype analysis of RNA from PBL, left capsule, and right capsule from patient #1 is illustrated in Figure 3 . As expected, a polyclonal pattern of TCR BV gene expression was detected in PBL ( Figure  3, lane 1) . In contrast, a more restricted or oligoclonal profile of TCR BV gene expression was detected in the patient's left and right capsules ( Figure 3, lanes 2 and  3, respectively) . While dissimilar patterns of restricted TCR gene expression were detected for the majority of BV genes surveyed, in some cases, amplification products with identical CDR3 lengths were detected between left and right capsules (e.g., Figure 3 , BV3 and BV13). These data suggested that an antigendriven clonal expansion might possibly account for the detection of identically sized TCR transcripts in both left and right SBI capsules.
To further examine the potential for antigen-driven T cell responses shared among inflammatory tissues, we focused our analysis on three SBI patients from whom, in two cases, multiple biopsies of clinically affected tissues were available. Patients' PBL, left and right SBI capsules, and remote tissue biopsies, when available, were analysed by the TCR BV CDR3 spectratyping assay illustrated in Figure 3 . A comprehensive alignment of BV CDR3 spectratype data obtained from each patient's tissues was conducted in an effort to identify size-restricted TCR transcripts shared among multiple, physically remote sites of inflammation (data not shown). Two TCR BV gene families with transcripts exhibiting shared CDR3 lengths among multiple inflammatory tissues were arbitrarily chosen from each patient for further analysis (Figure 4) . For patient #1, a 162 bp TCR BV13 amplification product was detected from both left and right SBI capsules (LC and RC, respectively), skeletal muscle (SM), and three independent skin biopsies (SK1, chest; SK2, vasculitic lesion-right hand; SK3, vasculitic lesion-left hand) ( Figure 4A, left panel) . A TCR BV3 fragment (199 bp) shared among both SBI capsules, skeletal muscle, and one skin biopsy (SK2) was also detected from this same patient, ( Figure 4A, right panel) . Similarly, TCRs bearing identical CDR3 lengths were detected in capsules and two axillary lymph nodes (LN1 and LN2) from patient #2 (BV18, 149 bp and BV24, 149 bp) and from both the left and right capsules of patient #3 (BV14, 197 bp; BV21, 196 bp) ( Figure 4B & C, respectively). While intriguing, the detection of common, size-restricted TCR transcripts shared among multiple tissues does not confirm that identical or similar T cell clones are present among these tissue infiltrates (i.e., TCRs with identically sized CDR3 regions may have unrelated amino acid sequences). To resolve this question, we next determined the clonal identity of these shared transcripts by direct DNA sequence analysis of the CDR3 antigen binding region.
Assessment of T cell clonality by TCR sequence analysis
To assess T cell clonality, we gel-purified, cloned, and determined the amino acid sequences of the TCR BV amplification products shared among multiple tissues in these patients. As shown in Figure 5A , an amino acid sequence alignment of BV13 transcripts (162 bp) isolated from patient #1 revealed a heterogeneous pattern of TCR gene expression among tissues. As expected, multiple, unrelated clonotypes (i.e., independently rearranged TCR genes) sharing identical CDR3 lengths were detected among PBL reflecting the polyclonal nature of circulating T lymphocytes. A polyclonal pattern of BV13 gene expression was also detected among T cells infiltrating a vasculitic skin lesion (SK3). A more restricted or oligoclonal pattern of BV13 gene expression was detected among the remaining tissues (LC, RC, SM, SK1, and SK2). There was no obvious amino acid sequence similarity within the CDR3 antigen binding domain detected among these BV13 tissue-infiltrating T cells. In contrast, a similar analysis of BV3 transcripts (199 bp) isolated from the same patient revealed that identical T cell clones were present among multiple, remote inflammatory tissues ( Figure 5B ). Two BV3 clones (CDR3 sequences: RYVA/GEL and EGV/QETQ) were detected among the otherwise polyclonal capsular infiltrates and the oligoclonal infiltrate seen in skeletal muscle. Of interest, the clonotype defined by the EGV/QETQ sequence was also detected among circulating T cells. One of the shared TCR clonotypes (RYVA/GEL) represented the predominant transcript detected among BV3 T cells infiltrating skeletal muscle and a vasculitic skin lesion (SK2).
A similar analysis of CDR3 amino acid sequences of TCR BV18 and BV24 transcripts (149 bp) was performed in specimens from patient #2 ( Figure 6A , left and right panels, respectively). While a single BV24 clonotype was detected from each of the SBI capsules, these clones lacked amino acid sequence identity with one another and with BV24 clones isolated from axillary lymph nodes (LN1 and LN2). In contrast, an identical BV18 clone (CDR3 sequence: PGPTH/EQ) was detected in both left and right capsules as well as within a more polyclonal lymph node population (LN1). Figure 6B summarizes an analysis of BV14 (197 bp) and BV21 (196 bp) capsular-infiltrating T cells from patient #3 (left and right panels, respectively). In this case, identical BV14 clones (CDR3 sequence: PTSED/EQ) represented the predominant clonotypes shared between left and right SBI capsules. Two distinct BV14 clonotypes (STVAG/EQ and STAAG/ EQ) that differed by only a single, conservative amino acid substitution (V/A) within the CDR3 domain were also detected in the right capsule ( Figure 6C ). No apparent amino acid sequence similarities were noted among BV21 capsular-infiltrating T cells from this patient ( Figure 6B , right panel).
Discussion
T lymphocytes are a prominent feature of inflammatory infiltrates in some SBI capsules [11] [12] [13] . When present, activated CD4+and CD8+T cells are often seen surrounding tissue vacuoles and macrophages containing a highly refractile, foreign material morphologically consistent with silicone (e.g. see Figure 1 ). It remains unclear, however, whether capsule-infiltrating T cells are antigen-driven or if they comprise a secondary, non-specific component of an otherwise benign foreign body response. We hypothesized that among capsule-infiltrating T cells, a subpopulation of antigen-driven cells may contribute to chronic inflammation in these and possibly remote sites of tissue injury.
It has been demonstrated in both humans and animal models that antigen-reactive, pathogenic T cells comprise a minority of infiltrating T cells in chronic inflammatory lesions [33, 34] . In these cases, the majority of T cells in chronic lesions likely represent secondary, bystander cells attracted by proinflammatory migratory signals [33, 52] . It is clear that the TCR CDR3 domain serves as a primary specificity determinant for T cell antigen recognition [42] . In fact, the detection of T cells expressing restricted and conserved TCR CDR3 sequence rearrangements is considered a hallmark of antigenic reactivity. For these reasons, we chose the TCR CDR3 spectratyping technique as a means of screening heterogeneous populations of tissue-infiltrating T cells to assess if T cell clones were shared among multiple pathologic lesions [40, 48] .
In an effort to identify putatively antigen-reactive T cells, we determined the pattern of TCR BV gene expression in SBI capsules and remote inflammatory tissues using a combination of CDR3 spectratyping and DNA sequence analysis. Overall, the number and identity of TCR BV gene families detected varied considerably among tissues and patients ( [13] and data not shown). By comparing CDR3 sizefractionated BV gene transcripts (i.e., spectratypes), we identified common, size-restricted transcripts shared among multiple inflammatory tissues ( Figures  3 & 4) . DNA sequence analysis confirmed that, at least in some cases, identical T cell clones are found at sites of local (i.e., left and right capsules) and remote inflammation (Figures 5 & 6) . The most dramatic example was the detection of a unique TCR BV3 clone (RYVA/GEL) in both left and right SBI capsules, skeletal muscle, and a vasculitic skin lesion isolated from patient #1 ( Figure 5 ). In contrast, a parallel analysis of BV13 clones isolated from the same patient's tissues failed to identify a shared clonotype(s). This distinction between the pattern of BV3 and BV13 gene expression emphasizes the importance of direct DNA sequence analysis of amplification products that are size-restricted on polyacrylamide gels. In one case, the BV13 clones identified likely represent bystander T cells which coincidentally share CDR3 lengths but not sequence, while the identical BV3 clones identified from multiple tissues appear to be selected and expanded by a common antigen(s). Interestingly, one or more identical T cell clones were detected in both left and right SBI capsules from each of the three patients analysed (Figures 5 & 6) . We did not, however, detect any TCR clones shared among different patients despite the fact that two patients expressed identical HLA DRB1 and DQA1 antigens (see Materials and Methods). Based upon the transcript detection limit of our assay (10 2 -10 3 T cells as described in Materials and Methods), these data are consistent with the clonal expansion of a limited or restricted number of antigen-reactive T cells. Moreover, the detection of two, distinct TCR clonotypes (STVAG/EQ and STAAG/EQ) utilizing identical BV14 and BJ2S7 gene segments and differing by only a single, conservative amino acid substitution (V/A) within the CDR3 antigen binding domain ( Figure 6C ), is additional evidence for antigenic selection of capsule-infiltrating T cells. Taken together, these data suggest that the same antigen-reactive T cell clones are present in SBI capsular infiltrates and remote inflammatory tissues. These findings are consistent with the detection of identical TCR clonotypes at multiple sites of inflammation from patients with autoimmune diseases including multiple sclerosis, psoriasis, Sjogren's syndrome, and rheumatoid arthritis [35, 37, 39, 41] .
The identification of an antigen responsible for initiating and/or promoting chronic inflammation in SBI capsules and possibly in remote tissues has remained elusive. It is well documented that silicone gel diffuses from implant devices (referred to as 'silicone bleed') and that SBIs rupture in a timedependent manner [1, 10, 30, 53, 54] . In either case, it is not uncommon for the body to be exposed to free silicone gel for extended periods of time. Several investigators employing in vitro T cell stimulatory assays have suggested that some silicones or siliconeconjugates may themselves provide an antigenic stimulus [5, 21, 22] . Alternatively, the strong adjuvant properties of certain silicones may render some endogenous proteins immunogenic [7, 16, 25] . Kossovsky and Freiman proposed that silicone, being very hydrophobic, may act as a powerful denaturant of capsule-associated connective tissue proteins (e.g. collagen) [7] . Recognition of denatured protein antigens by T cells might possibly initiate a broadening T cell response to multiple, formerly non-immunogenic epitopes of endogenous proteins. This model of epitope or determinant spreading has been well documented for a number of T cell antigens in various experimental and human autoimmune diseases [55, 56] . In fact, the generation of abnormal humoral (i.e., autoantibody production) and cellular immune responses to connective tissue proteins has been associated with silicone implantation [19, 25, 57] .
In the present study, we examined patterns of TCR gene expression from SBI patients including two from which multiple, concurrent inflammatory tissue biopsies were available. Ours is the first report documenting that a limited number of distinct TCR clonotypes, presumably expanded by an antigen-driven process, are shared among the inflammatory infiltrates in patients' capsules and, in some cases, remote inflammatory lesions. Unfortunately, the analysis of chronic inflammatory lesions from patients with established disease does not permit a determination of when, where, or how these shared T cell clones arose. Moreover, our laboratory has previously documented shared patterns of TCR V gene expression among capsules from asymptomatic SBI recipients ( [13] and unpublished results). Thus it is unclear whether the shared T cell clones identified in this study are the result of silicone exposure or an unrelated immune process or disease state [33, 52] . Nevertheless, the detection of identical T cell clones at multiple pathologic sites in the same patient suggests that a shared antigenic stimulus may contribute to chronic inflammation at these sites.
The basis for the variability in the degree of inflammation detected among the capsules from different SBI recipients remains unknown. It seems plausible, however, that subjects might vary in their sensitivity to silicone and that different individuals, defined by unique immunogenetics and environmental exposures, may experience diverse spectra of immunologic and clinical outcomes [58, 59] . Studies are on-going to determine the mechanisms that regulate SBI capsule formation and the pathophysiologic role of capsuleinfiltrating T cells.
